Desmopressin Farmacia: Uses, Dosage & Side Effects
Synthetic vasopressin analogue for diabetes insipidus, nocturnal enuresis and bleeding disorders
Quick Facts About Desmopressin Farmacia
Key Takeaways About Desmopressin Farmacia
- Restrict fluid intake: You must limit fluid intake from 1 hour before to 8 hours after taking desmopressin to prevent dangerous hyponatraemia (low sodium)
- Multiple indications: Treats central diabetes insipidus, bedwetting in children aged 5+, and nocturia in adults with nocturnal polyuria
- Monitor sodium levels: Serum sodium should be checked before starting treatment and monitored regularly, especially in elderly patients and children
- Different formulations are not interchangeable: Oral tablets and sublingual tablets have different dosing due to different bioavailability; a 60 mcg sublingual tablet is roughly equivalent to a 0.1 mg oral tablet
- Interrupt treatment periodically: For bedwetting and nocturia, treatment should be paused after 3 months to reassess the need for continued therapy
What Is Desmopressin Farmacia and What Is It Used For?
Desmopressin Farmacia is a synthetic analogue of vasopressin (antidiuretic hormone, ADH) that reduces urine production by acting on V2 receptors in the kidneys. It is used to treat central diabetes insipidus, primary nocturnal enuresis (bedwetting) in patients aged 5 years and older, and nocturia associated with nocturnal polyuria in adults.
Desmopressin is a modified form of the naturally occurring hormone vasopressin, which is produced by the posterior pituitary gland. The modification involves removing the amino group from position 1 and replacing L-arginine with D-arginine at position 8, which results in a molecule that has approximately 10 times the antidiuretic potency of natural vasopressin but with minimal effects on blood pressure. This selective action on V2 receptors makes desmopressin a highly effective and safe treatment for conditions characterised by excessive urine production.
In central diabetes insipidus, the body fails to produce sufficient vasopressin, leading to excessive urine production (polyuria) and extreme thirst (polydipsia). This condition may arise from damage to the hypothalamus or pituitary gland due to surgery, trauma, tumours, or autoimmune processes. Desmopressin replaces the missing hormone, restoring normal urine concentration and dramatically improving quality of life. Patients with diabetes insipidus typically require lifelong treatment with dose adjustments guided by urine output and serum sodium levels.
Primary nocturnal enuresis (bedwetting) is a common condition affecting approximately 5-10% of children aged 7 and 1-2% of adolescents. Desmopressin is one of the most well-established pharmacological treatments for this condition. It works by reducing nighttime urine production, allowing the bladder capacity to accommodate the urine produced during sleep. According to NICE guidelines and the International Children's Continence Society (ICCS), desmopressin is recommended when alarm therapy alone has been insufficient or is not suitable. Response rates typically range from 60-70%, with complete dryness achieved in approximately 30% of children.
Nocturia with nocturnal polyuria is a condition where adults produce an abnormally large volume of urine during the night, leading to frequent waking. The EMA has approved low-dose desmopressin (sublingual formulations) for this indication in adults under 65 who have nocturnal polyuria and who do not have other underlying conditions causing the symptom. Treatment can significantly reduce the number of nighttime voids and improve sleep quality.
In certain formulations (particularly intranasal and injectable), desmopressin is also used to increase levels of factor VIII and von Willebrand factor in patients with mild haemophilia A and type 1 von Willebrand disease. This haemostatic effect is mediated through V2 receptor stimulation of endothelial cells and is used to prevent or treat bleeding episodes during minor surgical procedures. Desmopressin can also be used as a diagnostic tool to test renal concentrating capacity.
What Should You Know Before Taking Desmopressin Farmacia?
Before taking Desmopressin Farmacia, your doctor must assess your kidney function and serum sodium levels. The most critical safety consideration is the risk of hyponatraemia (dangerously low blood sodium), which can cause seizures and cerebral oedema. Fluid intake must be strictly restricted during treatment.
Contraindications
Desmopressin Farmacia must not be used in the following situations:
- Habitual or psychogenic polydipsia (excessive water drinking due to habit or psychological reasons) – greatly increases the risk of water intoxication and hyponatraemia
- Known or suspected cardiac insufficiency and other conditions requiring treatment with diuretics – fluid retention can worsen heart failure
- Moderate to severe renal insufficiency (GFR below 50 mL/min) – impaired kidney function increases the risk of hyponatraemia
- Known hyponatraemia (serum sodium below 135 mmol/L) – desmopressin would further dilute blood sodium
- Syndrome of Inappropriate Antidiuretic Hormone secretion (SIADH) – desmopressin mimics the excessive ADH already present
- Hypersensitivity to desmopressin acetate or any of the excipients in the formulation
Warnings and Precautions
The most important safety concern with desmopressin is hyponatraemia (low blood sodium), which can be life-threatening. This occurs when excessive fluid is consumed while desmopressin prevents the kidneys from excreting water normally. Symptoms of hyponatraemia include headache, nausea, vomiting, weight gain, and in severe cases, seizures and cerebral oedema. To minimise this risk:
- Restrict fluid intake from 1 hour before administration to at least 8 hours after dosing
- Measure serum sodium before initiating treatment and at day 3, day 7, and one month after starting, then periodically thereafter
- Suspend treatment during acute illness with fluid and electrolyte imbalance (vomiting, diarrhoea, systemic infections)
- Exercise caution in elderly patients (aged 65 and over) who have a higher risk of hyponatraemia
- Avoid concomitant use of medications that increase risk of hyponatraemia (see interactions section)
Failure to restrict fluid intake while taking desmopressin can lead to water intoxication and severe hyponatraemia, which may result in seizures, loss of consciousness, and potentially fatal cerebral oedema. Patients, parents, and caregivers must be thoroughly educated about the importance of fluid restriction. Evening meals should not include excessive fluid, and drinking should be minimised from 1 hour before taking the dose until the next morning.
Special caution is required in patients with conditions that may be aggravated by fluid retention, including cystic fibrosis, bladder dysfunction, or conditions associated with electrolyte imbalance. In patients with coronary artery disease or hypertension, the mild antidiuretic effect may lead to transient fluid retention. Patients should be advised to stop taking desmopressin during episodes of fever, gastroenteritis, or other acute illnesses, and to resume only when fully recovered and eating and drinking normally.
Pregnancy and Breastfeeding
Data from a limited number of pregnancies (more than 50 but fewer than 300 exposed pregnancies reported in the literature) have not indicated adverse effects of desmopressin on pregnancy or foetal/neonatal health. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. Desmopressin should be used during pregnancy only when clearly necessary and when the benefit to the mother outweighs the potential risk to the foetus, particularly for women with diabetes insipidus who require ongoing treatment to prevent dangerous dehydration.
Results from analyses of breast milk from mothers receiving high doses of desmopressin (300 mcg intranasally) showed that the amounts of desmopressin transferred to the infant are considerably less than the doses required to produce an antidiuretic effect in the newborn. The European Medicines Agency (EMA) and most international guidelines consider desmopressin compatible with breastfeeding when used at standard therapeutic doses, though monitoring of the infant for signs of fluid retention is advisable.
How Does Desmopressin Farmacia Interact with Other Drugs?
The most clinically significant drug interactions with desmopressin involve medications that can increase the risk of hyponatraemia or that affect its antidiuretic action. Particular caution is needed with tricyclic antidepressants, SSRIs, NSAIDs, carbamazepine, and chlorpromazine, all of which can potentiate desmopressin's water-retaining effect.
Drug interactions with desmopressin are primarily related to two mechanisms: substances that potentiate the antidiuretic effect (increasing hyponatraemia risk) and substances that attenuate it (reducing therapeutic efficacy). Understanding these interactions is essential for safe prescribing and monitoring.
Major Interactions
The following drugs can increase the risk of hyponatraemia when used with desmopressin and require careful monitoring or dose adjustment:
| Drug / Drug Class | Mechanism | Clinical Significance | Action Required |
|---|---|---|---|
| Tricyclic antidepressants (e.g. amitriptyline, imipramine) | Potentiate antidiuretic effect via central mechanisms | High – significantly increased risk of water retention | Monitor sodium closely; consider dose reduction |
| SSRIs (e.g. fluoxetine, sertraline) | Can cause SIADH independently; additive hyponatraemia risk | High – SSRIs themselves frequently cause hyponatraemia | Frequent sodium monitoring; avoid combination if possible |
| Carbamazepine / Oxcarbazepine | Potentiate ADH effect; carbamazepine causes SIADH | High – well-documented interaction | Monitor sodium; may need to avoid combination |
| Chlorpromazine | Enhances release and effect of ADH | Moderate to high | Monitor sodium and fluid balance |
| NSAIDs (e.g. indomethacin, ibuprofen) | Reduce renal water excretion; potentiate antidiuretic effect | Moderate – indomethacin most significant | Monitor sodium; use paracetamol as alternative analgesic |
| Loperamide | Increases desmopressin plasma levels (up to 3-fold) | Moderate – pharmacokinetic interaction | Avoid concurrent use or reduce desmopressin dose |
Interactions That May Reduce Efficacy
Some drugs can reduce the antidiuretic effect of desmopressin, potentially leading to inadequate therapeutic response:
| Drug / Drug Class | Mechanism | Action Required |
|---|---|---|
| Lithium | Blocks V2 receptor signalling in collecting ducts; causes nephrogenic diabetes insipidus | May require higher desmopressin doses; monitor urine output |
| Demeclocycline | Antagonises ADH effect on renal tubules | Avoid combination; used therapeutically to counteract ADH |
| Alcohol | Inhibits endogenous ADH release; may counteract desmopressin | Avoid excessive alcohol; may reduce treatment efficacy |
| Glibenclamide (glyburide) | May reduce antidiuretic effect (mechanism not fully established) | Monitor urine output if combination is necessary |
Taking desmopressin with food reduces its absorption by approximately 40%. For consistent therapeutic effect, desmopressin should be taken at the same time relative to meals. Many prescribers recommend taking it on an empty stomach or at least 1.5 hours after a meal for optimal absorption.
What Is the Correct Dosage of Desmopressin Farmacia?
The dosage of Desmopressin Farmacia varies by indication, formulation, and patient age. For diabetes insipidus, the typical adult dose is 0.1-0.2 mg taken 2-3 times daily. For nocturnal enuresis in children aged 5+, the starting dose is 0.2 mg at bedtime. Doses must be individually titrated based on clinical response and serum sodium monitoring.
Desmopressin dosing requires careful individualisation. The oral bioavailability is low (approximately 0.08-0.16%), meaning that the dose delivered to the systemic circulation is a small fraction of the oral dose. Sublingual formulations have higher bioavailability, so their doses are lower. It is critical that patients do not switch between oral and sublingual formulations without medical supervision, as they are not directly interchangeable.
Adults
| Indication | Oral Tablet Dose | Sublingual Dose | Frequency | Notes |
|---|---|---|---|---|
| Central diabetes insipidus | 0.1–0.2 mg per dose | 60–120 mcg per dose | 2–3 times daily | Titrate to urine output; typical total daily dose 0.2–1.2 mg oral |
| Nocturia (nocturnal polyuria) | 0.1 mg at bedtime | 60 mcg at bedtime | Once daily | May increase to 0.2 mg / 120 mcg after 1 week if insufficient response |
| Primary nocturnal enuresis | 0.2 mg at bedtime | 120 mcg at bedtime | Once daily | May increase to 0.4 mg / 240 mcg if needed; review after 3 months |
Children (Aged 5 Years and Older)
Desmopressin is approved for the treatment of primary nocturnal enuresis in children aged 5 years and older, and for central diabetes insipidus at any age. The dosing recommendations for children are as follows:
Nocturnal Enuresis (Children aged 5+)
- Starting dose: 0.2 mg oral tablet (or 120 mcg sublingual) at bedtime
- Dose adjustment: May be increased to 0.4 mg oral (or 240 mcg sublingual) if inadequate response after 1-2 weeks
- Duration: Initial treatment period of 3 months, followed by a 1-week drug-free interval to reassess need
- Fluid restriction: Limit fluid intake from 1 hour before dose to 8 hours after; evening meals should not include excessive fluid
- Monitoring: Check serum sodium before starting and periodically during treatment; weigh the child regularly
Central Diabetes Insipidus (Children)
- Starting dose: 0.05–0.1 mg oral tablet, 2–3 times daily
- Dose adjustment: Titrate according to urine output and serum sodium; total daily dose typically 0.1–0.8 mg
- Monitoring: More frequent sodium monitoring in younger children; parents should be educated about signs of hyponatraemia
Elderly Patients (65 Years and Older)
Elderly patients are at significantly higher risk of hyponatraemia due to age-related changes in renal function, reduced total body water, and frequently concurrent medications that affect sodium balance. The EMA SmPC and multiple international guidelines recommend the following considerations:
- Nocturia: Low-dose sublingual desmopressin (25–50 mcg) has been specifically studied in elderly populations. However, the EMA-approved products for nocturia generally carry a warning against use in patients aged 65 and over, or recommend use only with intensive sodium monitoring
- Diabetes insipidus: Start at the lowest effective dose and monitor serum sodium more frequently (e.g. at baseline, day 3, day 7, then monthly)
- General precaution: Renal function should be assessed before starting treatment and regularly thereafter
Missed Dose
If you miss a dose of desmopressin, take it as soon as you remember, provided it is not too close to the next scheduled dose. For diabetes insipidus, a missed dose may lead to rapid onset of symptoms (excessive urination and thirst) – take the missed dose when you notice symptoms returning. For nocturnal enuresis or nocturia, if you remember at or after bedtime, take the dose but ensure you follow fluid restriction guidelines. Never take a double dose to compensate for a missed one, as this significantly increases the risk of water intoxication and hyponatraemia.
Overdose
An overdose of desmopressin leads to prolonged and excessive antidiuretic effect, resulting in water retention and progressive dilutional hyponatraemia. Symptoms of overdose may include:
- Headache, nausea, vomiting
- Rapid weight gain due to fluid retention
- Reduced or absent urine output
- Confusion, drowsiness
- In severe cases: seizures, loss of consciousness, cerebral oedema
There is no specific antidote for desmopressin. Treatment of overdose involves immediate discontinuation of the drug, strict fluid restriction, and monitoring and correction of serum sodium. In cases of severe symptomatic hyponatraemia (seizures, altered consciousness), cautious administration of hypertonic saline (3% NaCl) may be necessary under specialist supervision. The rate of sodium correction must be carefully controlled to avoid osmotic demyelination syndrome. Contact your local poison control centre or seek emergency medical attention immediately in case of suspected overdose.
What Are the Side Effects of Desmopressin Farmacia?
The most common side effects of desmopressin include headache, nausea, and abdominal pain. The most serious side effect is hyponatraemia (low blood sodium), which can lead to seizures and cerebral oedema if fluid intake is not properly restricted. Most side effects are dose-related and can be managed through proper fluid restriction and sodium monitoring.
Like all medicines, Desmopressin Farmacia can cause side effects, although not everybody gets them. The frequency and severity of side effects are strongly related to compliance with fluid restriction guidelines and the dose used. The following side effects have been reported based on clinical trials and post-marketing surveillance data from international regulatory agencies (EMA, FDA):
Common (affects 1–10 in 100 patients)
- Headache
- Nausea
- Abdominal pain
- Dry mouth
- Dizziness
Uncommon (affects 1–10 in 1,000 patients)
- Hyponatraemia (with or without symptoms)
- Oedema (fluid retention, swelling)
- Weight gain
- Fatigue
- Insomnia
- Vomiting
- Diarrhoea
- Nasal congestion (nasal formulations)
- Epistaxis – nosebleed (nasal formulations)
Rare (affects fewer than 1 in 1,000 patients)
- Severe hyponatraemia with seizures
- Cerebral oedema (life-threatening complication of severe hyponatraemia)
- Allergic reactions (rash, urticaria, anaphylaxis)
- Hypertension (transient, more common with high-dose parenteral use)
- Emotional disturbances in children
- Nightmares
The risk of hyponatraemia is the primary safety concern with desmopressin therapy. In clinical trials for nocturnal enuresis, the incidence of significant hyponatraemia (serum sodium below 130 mmol/L) was approximately 3-5% when patients adhered to fluid restriction guidelines, but could be substantially higher without proper fluid management. Elderly patients, particularly those taking concomitant medications that affect sodium balance, are at the greatest risk.
If you experience any of the following symptoms, stop taking desmopressin and seek medical attention immediately: persistent headache, nausea or vomiting, unusual drowsiness or confusion, rapid weight gain, swelling of hands or feet, or seizures. These may indicate developing hyponatraemia that requires urgent medical assessment.
If you experience side effects not listed here or if any side effects become serious, please inform your doctor or pharmacist. You can also report side effects directly to your national pharmacovigilance authority (e.g. MHRA Yellow Card Scheme in the UK, FDA MedWatch in the US, or the EMA through your national regulatory agency). By reporting side effects, you can help provide more information on the safety of this medicine.
How Should You Store Desmopressin Farmacia?
Store Desmopressin Farmacia at room temperature below 25°C (77°F), protected from moisture and light. Keep in the original packaging until use. Nasal spray formulations should be stored upright and used within the specified time after first opening.
Proper storage of desmopressin is important to maintain its potency and safety. As a peptide hormone analogue, desmopressin can be sensitive to environmental conditions. Follow these storage guidelines:
- Oral and sublingual tablets: Store below 25°C (77°F) in the original blister packaging to protect from moisture. Do not remove sublingual tablets from the blister until immediately before use, as they are hygroscopic
- Nasal spray: Store upright below 25°C. Once opened, nasal spray formulations typically have a limited in-use shelf life (usually 4–8 weeks depending on the manufacturer). Record the date of first opening on the bottle
- Injectable solutions: Store in a refrigerator (2–8°C / 36–46°F) unless the product labelling specifies otherwise. Protect from light. Do not freeze
- General: Keep out of the sight and reach of children. Do not use after the expiry date stated on the packaging. Do not dispose of medicines via wastewater or household waste; return unused medicines to your pharmacy for proper disposal
What Does Desmopressin Farmacia Contain?
The active substance in Desmopressin Farmacia is desmopressin acetate, a synthetic analogue of vasopressin. Each formulation contains different inactive ingredients (excipients) appropriate to the dosage form. Patients with known intolerances to specific excipients should review the full list with their pharmacist.
Desmopressin acetate is the active pharmaceutical ingredient in all Desmopressin Farmacia formulations. The chemical name is 1-deamino-8-D-arginine vasopressin monoacetate, with the molecular formula C46H64N14O12S2·C2H4O2 and a molecular weight of approximately 1129.3 g/mol. It is a white powder freely soluble in water.
Typical excipients found in desmopressin oral tablet formulations include:
- Lactose monohydrate (patients with rare hereditary problems of galactose intolerance should not take this formulation)
- Potato starch
- Povidone
- Magnesium stearate
- Stearic acid
Sublingual (melt/lyophilisate) tablet excipients typically include:
- Gelatin
- Mannitol
- Citric acid anhydrous
The exact composition of excipients may vary between manufacturers and specific product formulations. Always consult the patient information leaflet provided with your specific product for the complete list of ingredients. If you have known allergies or intolerances (particularly lactose intolerance), discuss this with your pharmacist before starting treatment.
Frequently Asked Questions About Desmopressin Farmacia
Desmopressin Farmacia is a synthetic vasopressin analogue used primarily for treating central diabetes insipidus (a condition where the body cannot concentrate urine properly), primary nocturnal enuresis (bedwetting) in patients aged 5 years and older, and nocturia associated with nocturnal polyuria (excessive nighttime urination) in adults. In certain formulations, it is also used to manage mild haemophilia A and type 1 von Willebrand disease by increasing clotting factors, and as a diagnostic tool to assess renal concentrating capacity.
The most serious side effect is hyponatraemia (dangerously low blood sodium levels), which can lead to headache, nausea, vomiting, confusion, seizures, and in severe cases, life-threatening cerebral oedema. This risk is directly related to fluid intake – patients must strictly restrict fluids from 1 hour before to 8 hours after taking desmopressin. Elderly patients and those taking certain medications (SSRIs, tricyclic antidepressants, NSAIDs, carbamazepine) are at highest risk. Regular monitoring of serum sodium is essential.
Yes, desmopressin is one of the most commonly prescribed and well-studied medications for primary nocturnal enuresis in children aged 5 years and older. The typical starting dose is 0.2 mg taken at bedtime with minimal fluid. If the response is inadequate after 1–2 weeks, the dose may be increased to 0.4 mg. Treatment should be reviewed after 3 months with a drug-free interval to assess whether the child still needs the medication. Parents must ensure strict fluid restriction during treatment to prevent hyponatraemia.
Food reduces the absorption of oral desmopressin by approximately 40%. For the most consistent effect, it is best to take desmopressin on an empty stomach or at least 1.5 hours after eating. For sublingual (melt) tablets, place the tablet under the tongue and allow it to dissolve completely without chewing or swallowing it whole; the sublingual route is less affected by food. Regardless of formulation, always restrict fluid intake from 1 hour before to 8 hours after the dose.
Oral desmopressin tablets (0.1 mg, 0.2 mg) are swallowed with a small amount of water and have a relatively low bioavailability. Sublingual (melt) tablets (60 mcg, 120 mcg, 240 mcg) dissolve under the tongue and are absorbed through the oral mucosa, providing higher bioavailability. A 60 mcg sublingual tablet is approximately equivalent to a 0.1 mg oral tablet. The two formulations are not directly interchangeable, and switching between them requires medical supervision and potentially dose adjustment. Sublingual tablets do not require water and may be preferred for children or patients who have difficulty swallowing.
Alcohol should be avoided or strictly limited while taking desmopressin for several reasons. First, alcohol inhibits the release of natural vasopressin, which can partially counteract desmopressin's therapeutic effect. Second, alcoholic beverages contribute to fluid intake, which must be restricted with desmopressin. Third, alcohol can impair judgement about fluid consumption and make it harder to adhere to necessary fluid restriction. If you do consume alcohol, keep it minimal and account for the volume as part of your fluid restriction. Discuss alcohol use with your prescriber.
References
This article is based on the following evidence-based sources. All medical claims are supported by Level 1A evidence from systematic reviews, randomised controlled trials, and authoritative clinical guidelines:
- European Medicines Agency (EMA). Summary of Product Characteristics – Desmopressin-containing medicinal products. Available at: www.ema.europa.eu. Accessed January 2026.
- U.S. Food and Drug Administration (FDA). DDAVP (desmopressin acetate) prescribing information. Available at: www.fda.gov. Accessed January 2026.
- World Health Organization (WHO). Model List of Essential Medicines, 23rd List (2023). Desmopressin is included as an essential medicine for diabetes insipidus. Geneva: WHO; 2023.
- British National Formulary (BNF). Desmopressin drug monograph. London: BMJ Group and Pharmaceutical Press; 2025.
- National Institute for Health and Care Excellence (NICE). Nocturnal enuresis: the management of bedwetting in children and young people. Clinical guideline CG111. Updated 2023.
- Vande Walle J, Stockner M, Raes A, et al. Desmopressin 30 years in clinical use: a safety review. Current Drug Safety. 2007;2(3):232-238. doi:10.2174/157488607781668891
- Rittig S, Knudsen UB, Norgaard JP, Pedersen EB, Djurhuus JC. Abnormal diurnal rhythm of plasma vasopressin and urinary output in patients with enuresis. American Journal of Physiology. 1989;256(4 Pt 2):F664-F671.
- Neveus T, Fonseca E, Franco I, et al. Management and treatment of nocturnal enuresis – an updated standardization document from the International Children's Continence Society. Journal of Pediatric Urology. 2020;16(1):10-19.
- Weiss JP, Zinner NR, Klein BM, Norgaard JP. Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double-blind, placebo-controlled trial. Neurourology and Urodynamics. 2012;31(4):441-447.
- Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first twenty years. Blood. 1997;90(7):2515-2521.
About Our Medical Editorial Team
This article has been written and medically reviewed by the iMedic Medical Editorial Team, consisting of licensed physicians specialising in clinical pharmacology, endocrinology, and nephrology. Our team follows the GRADE evidence framework and adheres to international guidelines from WHO, EMA, FDA, BNF, and NICE.
Content authored by specialist physicians with expertise in pharmacology and endocrinology. All drug information is cross-referenced with EMA SmPC, FDA labelling, and peer-reviewed literature.
Independently reviewed by the iMedic Medical Review Board. Evidence level 1A: based on systematic reviews, meta-analyses, and randomised controlled trials. Last reviewed: .
We maintain strict editorial independence with no commercial funding or pharmaceutical company sponsorship. For more information about our editorial standards, visit our Editorial Standards page. To contact our medical team, visit our Contact page.